Block view
- Organization
- Theory
- Practical
- Others
- Credits
Block 1
| Code | Details | Organization | Theory | Practical | Others | Credits |
|---|---|---|---|---|---|---|
| PHIN2034-1 | Biotechnologies | TA | 7 | |||
| Concepts and production of protein and oligonucleotide biopharmaceuticals
David Vermijlen
| 15 | - | - | |||
| Living biopharmaceuticals and vaccines - part A: concepts and biosecurity
Véronique Fontaine
| 6 | - | - | |||
| Living biopharmaceuticals and vaccines - part B: managing the risk of the release of cell and genetic products | 3 | - | - | |||
| Formulation of biopharmaceuticals
Rita Vanbever
| 15 | - | - | |||
| Quality control and analytical techniques in biopharmaceuticals, good practice, and legal recommendations - part A: analytical methods | 10 | - | - | |||
| Quality control and analytical techniques in biopharmaceuticals, good practice, and legal recommendations - part B: post-translational modifications
Cédric Delporte
| 3 | - | - | |||
| From the laboratory to the pharmacy: legal requirements - part A: patents and industrial protection
Patrick Di Stefano
| 5 | - | - | |||
| From the laboratory to the pharmacy: legal requirements - part B: specifics of regulation around biological drugs including advanced therapies | 5 | - | - | |||
| From the laboratory to the pharmacy: legal requirements - part C: procedure for releasing batches and the legal framework of vaccines
Lorenzo Tesolin
| 1 | - | - | |||
| From the laboratory to the pharmacy: legal requirements - part D: introduction to biobanking | 3 | - | - | |||
| PHIN2004-1 | Active substances | TA | 4 | |||
| Substances issues de recherches pharmacochimiques, part a | 5 | - | - | |||
| Substances issues de recherches pharmacochimiques, part b
François Dufrasne
| 5 | - | - | |||
| Substances d'origine naturelle, part a
Quentin Spillier
| 5 | - | - | |||
| Substances d'origine naturelle, part b
Caroline Stevigny
| 5 | - | - | |||
| Produits radiopharmaceutiques
Zena Wimana
| 10 | - | - | |||
| PHIN2008-2 | Clinical viewpoints | TA | 5 | |||
| Métabolisme des médicaments et paramètres pharmacocinétiques
François-Xavier Mathy
| 20 | - | - | |||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) | 15 | - | - | |||
| Information et pharmacovigilance | 10 | - | - | |||
| PHIN2013-2 | Quality assurance and pharmaceutical management | TA | 7 | |||
| Principles of pharmaceutical management | 10 | - | - | |||
| Quality assurance, part a: basic concepts and quality assurance organisation
Thierry Pronce
| 18 | - | - | |||
| Quality assurance, part b: analytical technology of procedures and risk analysis
Xavier Marcelis
| 10 | - | - | |||
| English applied to the pharmaceutical industry
Jacques Poupaert, Nevin Serbest
| 20 | - | - | |||
| Pharmaceutical marketing | 7,5 | - | - | |||
| PHIN2033-1
| Pharmaceutical technology | TA | 5 | |||
| Industrial pharmaceutical microbiology
Véronique Fontaine
| 9 | - | - | |||
| Preformulation and selection of galenical forms
Jonathan Goole
| 15 | - | - | |||
| Industrial production of galenical forms | 15 | - | - | |||
| Industrial aspects of technological development including packaging | 10 | - | - | |||
| PHIN2023-1 | Drug analysis | TA | 6 | |||
| Drug analysis methods using mass spectrometry
Pierre Van Antwerpen
| 6 | - | - | |||
| Pharmaceutical analysis and control methods, including sample preparation in drug matrices and analysis in biological media | 8 | - | - | |||
| Validation of analytical methods, equipment qualification procedures, implementation of pharmacopeia procedures, method transfer | 6 | - | - | |||
| Process analytical technology (PAT) | 6 | - | - | |||
| Statistic
Laure Elens
| 15 | - | - | |||
| Experimental planning and quality by design | 10 | - | - | |||
| Case studies in collegiality | 3 | - | - | |||
| PHIN2029-2 | Regulations and the medical-social environment | TA | 8 | |||
| Economic aspects of drug development | 10 | - | - | |||
| Belgian and European legislation and procedures applied to the pharmaceutical industry
Catherine Druez
| 15 | 5 | - | |||
| Organisation of social security, funding healthcare, and future developments | 5 | - | - | |||
| CTD file (common technical document) & qualified person duties and responsibilities | 15 | - | - | |||
| Regulations of preclinical and clinical studies - part A: pharmaceutical toxicological files
Karen Van Malderen
| 7,5 | - | - | |||
| Belgian and European legislation on clinical trials
Anne Lenaers
| 5 | - | - | |||
| Specific regulatory environment for preclinical and clinical pediatric drugs
Thierry Schurmans
| 2,5 | - | - | |||
| Specific regulatory issues, part a: medicine and herbal dietary supplements | 5 | - | - | |||
| Specific regulatory aspects, part b: preformulation and documentation of galenic development
Francis Vanderbist
| 5 | - | - | |||
| PHIN2032-1 | Visits and seminars organised in the pharmaceutical industry - [75h Visit]
François Dufrasne, Marianne Fillet, Jonathan Goole, Rita Vanbever
| TA | - | - | [+] | 3 |
| MTFE2000-1 | End-of-course work carried out during an internship in the pharmaceutical industry or in a university research lab - [12w Stage de contact]
François Dufrasne, Marianne Fillet, Joëlle Leclercq
| TA | - | - | [+] | 15 |